Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab
Cadonilimab is the first bi-specific antibody approved for certain malignancies in June 2022, which has a modified Fc structure to reduce immune-related adverse events. To date, no reports have described Cadonilimab-related toxic epidermal necrolysis (TEN). Here, we report the first case of TEN-like...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1188523/full |
| _version_ | 1797755415789830144 |
|---|---|
| author | Peng-Yu Chen Zi-Yun Li Sui-Qing Cai |
| author_facet | Peng-Yu Chen Zi-Yun Li Sui-Qing Cai |
| author_sort | Peng-Yu Chen |
| collection | DOAJ |
| description | Cadonilimab is the first bi-specific antibody approved for certain malignancies in June 2022, which has a modified Fc structure to reduce immune-related adverse events. To date, no reports have described Cadonilimab-related toxic epidermal necrolysis (TEN). Here, we report the first case of TEN-like reactions occurring during the treatment of hepatocellular carcinoma with Cadonilimab in combination with Lenvatinib and transarterial chemoembolization, successfully treated with supplemental Adalimumab. We confirmed Cadonilimab as the culprit and observed significant improvement in the patient’s condition following Adalimumab treatment. The case emphasizes the potential risk of Cadonilimab inducing TEN, and suggests that supplemental Adalimumab could be a favorable option for treating refractory Cadonilimab-related TEN. |
| first_indexed | 2024-03-12T17:47:32Z |
| format | Article |
| id | doaj.art-6f621f699d044ae68960c480dbd37f50 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-12T17:47:32Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-6f621f699d044ae68960c480dbd37f502023-08-03T12:45:45ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-08-011410.3389/fimmu.2023.11885231188523Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental AdalimumabPeng-Yu ChenZi-Yun LiSui-Qing CaiCadonilimab is the first bi-specific antibody approved for certain malignancies in June 2022, which has a modified Fc structure to reduce immune-related adverse events. To date, no reports have described Cadonilimab-related toxic epidermal necrolysis (TEN). Here, we report the first case of TEN-like reactions occurring during the treatment of hepatocellular carcinoma with Cadonilimab in combination with Lenvatinib and transarterial chemoembolization, successfully treated with supplemental Adalimumab. We confirmed Cadonilimab as the culprit and observed significant improvement in the patient’s condition following Adalimumab treatment. The case emphasizes the potential risk of Cadonilimab inducing TEN, and suggests that supplemental Adalimumab could be a favorable option for treating refractory Cadonilimab-related TEN.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1188523/fullcase reportCadonilimab/AK104toxic epidermal necrolysisAdalimumabimmune-related adverse eventsimmune checkpoint inhibitor |
| spellingShingle | Peng-Yu Chen Zi-Yun Li Sui-Qing Cai Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab Frontiers in Immunology case report Cadonilimab/AK104 toxic epidermal necrolysis Adalimumab immune-related adverse events immune checkpoint inhibitor |
| title | Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab |
| title_full | Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab |
| title_fullStr | Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab |
| title_full_unstemmed | Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab |
| title_short | Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab |
| title_sort | case report cadonilimab related toxic epidermal necrolysis like reactions successfully treated with supplemental adalimumab |
| topic | case report Cadonilimab/AK104 toxic epidermal necrolysis Adalimumab immune-related adverse events immune checkpoint inhibitor |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1188523/full |
| work_keys_str_mv | AT pengyuchen casereportcadonilimabrelatedtoxicepidermalnecrolysislikereactionssuccessfullytreatedwithsupplementaladalimumab AT ziyunli casereportcadonilimabrelatedtoxicepidermalnecrolysislikereactionssuccessfullytreatedwithsupplementaladalimumab AT suiqingcai casereportcadonilimabrelatedtoxicepidermalnecrolysislikereactionssuccessfullytreatedwithsupplementaladalimumab |